A new thiazolopyrimidine derivative 19 was reported to have a significant PDE5 inhibitory activity (IC50 = 0.046 nM) and a strong cytotoxic effect against MCF-7 breast cancer cells with IC50 of 8.56 ± 0.7μM [94–101]. This evidence concerns the gene PDE5A and breast carcinoma.